EMA Updates Brexit Guidance With Info for Generics Manufacturers

International Pharmaceutical Regulatory Monitor
A A
The European Medicines Agency and the European Commission broadened their guidance on Brexit to include new information for manufacturers of orphan drugs, generics and biosimilars, as well as hybrid medicines that rely on reference product data as well as new clinical trial findings.

To View This Article:

Login

Subscribe To International Pharmaceutical Regulatory Monitor